Matthew During

Matthew During, M.D., D.Sc., is our founder and served as our chief scientific officer from March 2015 to May 2019 and has been a member of our board of directors from April 2014 to May 2019. He served as our chief executive officer from April 2014 to March 2015. Prior to founding our company, Dr. During founded Nightstar Therapeutics, a gene therapy company, in October 2013 and served as a consultant until November 2015. He co-founded Vector Neurosciences, another gene therapy company in January 2014, serving as CEO, subsequently sold in October 2018 to MeiraGTX. Most recently, he founded Emrys Bio where he serves as President. From February 2014 to December 2014, Dr. During served as a senior manager at Bridgewater Associates. Prior to that, he founded Neurologix Inc., a pharmaceutical company, in October 1999 and served as a member of its scientific advisory board until March 2012. Dr. During also co-founded Merlin Pharmaceuticals Limited, a pharmaceutical company, in February 1993 and served as a member of its scientific advisory board until December 1994. Dr. During previously served on the faculty of Yale University as a professor of neurosurgery from 1989 to 2000, as a professor at Cornell University until 2006 and Ohio State University from 2006 to December 2014, where he currently serves as an adjunct professor. Since 2011, he has also served as a visiting professor of translational neuroscience at the University of Oxford. Dr. During earned his B.S., M.D. and D.Sc. from the University of Auckland. He also completed fellowships at Massachusetts Institute of Technology, Harvard Medical School, Massachusetts General Hospital and Yale University.